Non-selective beta-blocker use in cirrhotic patients is associated with a reduced likelihood of hospitalisation for infection.

Home use of NSBBs by patients with cirrhosis was associated with fewer infection-related admissions. The data suggest that NSBBs in this group of patients reduce the risk of infection.